Infliximab-Induced Organizing Pneumonia Resulting in Persistent Respiratory Impairment.

Infliximab is a biologic agent used to treat moderate-to-severe ulcerative colitis by inhibiting the TNF cytokine signaling. Off-target effects of TNF inhibitors include immune suppression and disruption of the tissue repair response. Previous case reports have linked infliximab to several patterns of acute pulmonary toxicity; however, the potential for severe infliximab-induced pneumonitis on long-term respiratory impairment remains largely uncharacterized.